DSIP Dosing Protocol: Sleep Enhancement Guide
Also known as: Delta Sleep-Inducing Peptide, Slow-Wave Sleep Nonapeptide
Studied in published research — not a medical recommendation. Primary protocol (Sleep Enhancement Protocol): 25-100 mcg, 30 minutes before bedtime.
30 minutes before bedtime
Research-reported range; the linked study used a different dose or units. Higher sleep efficiency and shorter sleep latency demonstrated in clinical trials
Subcutaneous or intranasal
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 200 doses in the vial at the low end (50 doses at the high end).
Save DSIP (Delta Sleep-Inducing Peptide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
DSIP (Delta Sleep-Inducing Peptide) supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Peptide?
A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.
Bottom Line Up Front
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide that promotes sleep. It was isolated from rabbit brain in 1977. Limited modern clinical trials but some evidence for sleep quality improvement.
Sleep quality, sleep regulation
Insomnia treatment (severe), anxiety
None
20 (9 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. DSIP (Delta Sleep-Inducing Peptide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
DSIP is a naturally occurring nonapeptide that was first isolated from rabbit cerebral venous blood during slow-wave sleep. It acts as a neuromodulator and has been shown to increase sleep efficiency, reduce sleep latency, and provide neuroprotective effects through antioxidant mechanisms.
Mechanisms of Action
- Modulates NMDA receptor activity in the brain
- Increases GABAergic transmission
- Stimulates acetyltransferase activity through α1 receptors
- Enhances superoxide dismutase (SOD) and glutathione peroxidase activity
- May regulate circadian rhythms through hypothalamic action
Research Protocols
Summaries of published research. For educational purposes only.
Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (DSIP (Delta Sleep-Inducing Peptide))
Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.
hs-CRP (High-Sensitivity C-Reactive Protein)
Day 0 + Wk 6–8Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.
Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.
ESR (Sedimentation Rate) & Ferritin
Day 0 + Wk 6–8Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.
Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.
CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)
Day 0 + Wk 6–8Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).
Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).
CMP (Liver/Kidney) + Serum Copper & Zinc Ratio
Day 0 + Wk 6–8Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.
Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.
Related Studies
Quite 100% of DSIP has been entrapped into positively charged Co-DMAEMA-MBAA matrix, while the quantity of DSIP adsorbed on negatively charged Co-AA-MBAA was only 2-6%. DSIP release from Co-DMAEMA-MBAA was observed in saline solutions (0.9% NaCl and PBS) while there was no DSIP release in water or 25% ethanol, thus ionic strength was a reason of this process.
Limitations: Animal study only — human translation uncertain.
ACTH (4-10) analogue injection inhibited stress-induced Fos expression in the pPVN and the medial septum, but only in predisposed rats. The experiments indicate that DSIP and ACTH (4-10) analogue reduce pPVN and limbic neurone responses to emotional stress in the rats predisposed to emotional stress; the effects on Fos expression may play a role in the biological activities of these peptides.
Limitations: Animal study only — human translation uncertain.
This assumption is based on: (i) a highly specific distribution of DSIP-like immunoreactivity in the neurosecretory hypothalamic nuclei of various vertebrate species that are not particularly relevant for sleep regulation, as revealed by the histochemical studies of the Geneva group (Charnay et al.); (ii) a large spectrum of DSIP biological activity revealed by biochemical and physiological studies in vitro; (iii) significant slow-wave sleep (SWS) promoting activity of certain artificial DSIP structural analogues (but not DSIP itself!) in rabbits and rats revealed by our early studies; and (iv) significant SWS-promoting activity of a naturally occurring dermorphin-decapeptide that is structurally similar to DSIP (in five of the nine positions) and the sleep-suppressing effect of its optical isomer, as revealed in rabbits. Potential future studies are outlined, including natural synthesis and release of this DSIP-like peptide and its role in neuroendocrine regulation.
Limitations: No placebo control reported. Review article — no new primary data.
Delta sleep-inducing peptide.
Human StudyDelta sleep-inducing peptide. (European journal of anaesthesiology, 2001)
Limitations: No placebo control reported. Review article — no new primary data.
CSF DSIP-LI was significantly correlated with polysomnography the night before the LP: with stage 3 sleep (p = 0.05), stage 3 and delta (stages 3 + 4) sleep during the first nonrapid eye movement NREM period (p = 0.02 and p = 0.05, respectively) and the ratio of the first and second NREM period (p < 0.05), and negatively with stage 2% sleep (p < 0.05). Whether this first report of a potential relationship between CSF DSIP-LI and slow-wave sleep in man might be generalized to sleep in nonpsychiatric subjects awaits further study.
Limitations: No placebo control reported.
Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP).
Animal StudyThese results suggest that DSIP produces an antinociceptive effect by acting at the supraspinal level and that this effect is mediated via the opioid receptor, either directly or indirectly. DSIP may play an important role in pain regulation in the central nervous system.
Limitations: Animal study only — human translation uncertain.
In all three species, high-performance liquid chromatography revealed a single peak of DSIP-like material with approximately the same retention time as DSIP 3-9. Taken together, the present results provide evidence for the presence of DSIP-LI in gut endocrine cells in man, pig and rat; the human gut seems to be the richest source of DSIP-like peptides.
Limitations: No placebo control reported.
Significant decreases of DSIP-LI compared with age-matched controls (C1) were observed for S2, S3, MD, PD, VD and H. In contrast, no significant differences corresponding to pathology were found for P-DSIP-LI.
Limitations: Standard limitations apply. Check original paper for full discussion.
Passage of delta sleep-inducing peptide (DSIP) across the blood-cerebrospinal fluid barrier.
Animal StudyThe clearance of DSIP from the ventricles during ventriculo-cisternal perfusion in the rabbit indicated no significant flux of the intact peptide out of the CSF. The results suggest that DSIP crosses the blood-CSF barrier, while the system lacks the specific mechanisms for removal from the CSF found with most, if not all, amino acids and several peptides.
Limitations: Animal study only — human translation uncertain.
A sleep-related increase in LH release is seen during puberty in man. It is possible that DSIP released within the hypothalamus may play a physiological role in sleep-related LH release.
Limitations: Animal study only — human translation uncertain.
Immunohistochemical as well as radioimmunochemical studies provided further insights into the natural occurrence of the nonpeptide and the distribution of DSIP-like material in the body, suggesting possible relations of the peptide to certain diseases. Various physiological functions of DSIP and a possible mechanism of action involving the modulation of adrenergic transmission remain to be established.
Limitations: No placebo control reported. Review article — no new primary data.
The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.
Animal StudyThe increase in S2 was caused by a prolongation of S2 episodes and not by their more frequent occurrence. The results obtained suggest a sleep-facilitating property of DSIP.
Limitations: Animal study only — human translation uncertain.
Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats.
Animal StudyHowever, DSIP (10(-8) or 10(-6)M) had no effect on either basal or luteinizing hormone-releasing hormone-induced in vitro LH release from the hemipituitaries of ovarian steroid-primed rats. These findings are in accord with the hypothesis that DSIP or DSIP-like peptide(s) may activate the hypothalamic neural circuitry responsible for stimulation of LH release reported to occur during sleep.
Limitations: Animal study only — human translation uncertain.
It was concluded that the rapid disappearance of injected DSIP in blood was due to degradation, whereas complex formation together with slower degradation resulted in longer persistence of apparently intact analogs. Whether this could explain the sometimes stronger and more consistent effects of DSIP-analogs remains to be examined.
Limitations: No placebo control reported.
There was no change in the amount of REM sleep. These findings support the belief that DSIP can increase sleep wave activity when administered by peripheral route.
Limitations: Animal study only — human translation uncertain.
DSIP-like material was found by RIA and immunohistochemistry in brain and by RIA in peripheral organs of the rat as well as in plasma of several mammals. In addition to sleep, the peptide also has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.
Limitations: No placebo control reported. Review article — no new primary data.
Digestion with trypsin, however, produced small immunoreactive peptides with only a minimal reduction in total immunoreactivity. Thus, DSIP-like material is widespread in peripheral tissues and appears to exist mainly in a large form, probably bound to protein, that can be reduced in size by tryptic digestion and can be dissociated at lower concentrations of tissue to yield small immunoreactive peptides.
Limitations: Animal study only — human translation uncertain.
The results cannot be explained by either regurgitation of intestinal contents, or by stimulation of endogenous peptide. They show that a DSIP peptide administered orally can be absorbed through the GI tract into the systemic circulation.
Limitations: Animal study only — human translation uncertain.
Results of 6-day consecutive intravenous administration (50 microgram/kg) indicate that there is no obvious sign of adaptation to DSIP. Results suggest that the physiological function of endogenous sleep-inducing peptide is different from that of general sleeping draught.
Limitations: Animal study only — human translation uncertain.
Sleep-promoting effects occurred only in the second hour after injection, in the first hour a slight arousing effect was indicated. The study corroborates the findings of previous investigations in healthy subjects and shows that DSIP has a normalizing influence on human sleep regulation.
Limitations: No placebo control reported.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •May cause vivid dreams or nightmares
- •Paradoxical alertness in some individuals
- •Not recommended for those with severe depression
- •Long-term human safety data limited
Where to get DSIP (Delta Sleep-Inducing Peptide), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy DSIP (Delta Sleep-Inducing Peptide): best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Ascension Peptides — $3.00/mg (10mg Lyophilized Vial, $30.00)
- 2. Direct Peptides — $4.90/mg (10mg vial, $49.00)
- 3. Elite Research USA — $5.50/mg (10mg vial, $55.00)
Where is the cheapest place to buy DSIP (Delta Sleep-Inducing Peptide)?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $3.00/mg (10mg Lyophilized Vial, $30.00 after the 50% new-customer partner-link discount). We compared 10 US suppliers with live, checked prices.
How much does DSIP (Delta Sleep-Inducing Peptide) cost per mg?
Verified US domestic prices currently range from $3.00/mg to $11.19/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is DSIP (Delta Sleep-Inducing Peptide) approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More cognitive peptides
Semax
Semax is a synthetic peptide derived from adrenocorticotropi...
Selank
Selank is a synthetic peptide derived from tuftsin. It has b...
Noopept (Omberacetam)
Noopept is a synthetic nootropic dipeptide developed in Russ...
Dihexa
Dihexa is a synthetic peptide derived from angiotensin IV th...
Cerebrolysin
Cerebrolysin is a porcine brain-derived peptide preparation ...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.